Bispecific Antibody Application in Osteology

Creative Biolabs has been entirely devoted to the development of bispecific antibody (BsAb) treatments and has received widespread recognition for its exceptional products and services. We deliver high-grade BsAb for osteology applications based on our well-established BsAb production infrastructure.

Introduction of Osteology

Bone is a living, growing tissue that protects soft organs and supports the body. A person may have a condition or disease that affects bone flexibility and strength, such as osteoporosis, osteogenesis imperfecta, osteonecrosis, osteomalacia, etc. Bone remodeling is a continual process in which the skeleton is renewed by highly regulated osteoblast-mediated bone production and osteoclast-mediated bone resorption. Tumors in the bones can affect bone remodeling. Wnt signaling is closely related to bone mass management, playing an important role in driving osteoblastogenesis and bone formation throughout growth, bone homeostasis, and fracture repair.

The tumor necrosis factor superfamily cytokine receptor activator of nuclear factor kappa-B ligand (RANKL), generated by osteoblasts, is an important regulator of bone remodeling. RANKL enhances the production and activity of osteoclasts by binding to its cell surface receptor (RANK) on osteoclasts and their progenitors, resulting in increased bone resorption, all of which stimulate bone tumor development. RANKL is also thought to be a chemotactic factor that influences tumor cell metastatic migration into bones.

Fig.1 RANK signaling pathways.¹

Advantages and Application of BsAbs in Osteology

In a multitude of domains, including osteology, BsAbs are interesting next-generation therapeutics. According to studies, bi-specific Wnt mimetics based on Frizzled and low-density lipoprotein receptor-related proteins generate rapid and robust bone building effects and repair BMD deficiency and bone abnormalities in a variety of disease models such as osteoporosis, aging, and long bone fracture². A first-in-class BsAb with combined inhibition of sclerostin and Wnt antagonist has been shown to lead to synergistic bone growth in mice and nonhuman primates³. Furthermore, by focusing on different aspects of fracture healing, the BsAb outperforms monotherapies in terms of bone repair activity.

Our Services

Creative Biolabs provides suitable techniques for synthesizing BsAbs for specific scientific and/or clinical research applications based on customer needs. Creative Biolabs, which has extensive experience in BsAb design and production, is available to assist customers in developing BsAbs to inhibit or activate signaling pathways involved in osteoclast differentiation and activity.